Cargando…
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
BACKGROUND: Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irradiation fields have been accompanied with an increased ris...
Autores principales: | König, Laila, Dreyling, Martin, Dürig, Jan, Engelhard, Marianne, Hohloch, Karin, Viardot, Andreas, Witzens-Harig, Mathias, Kieser, Meinhard, Klapper, Wolfram, Pott, Christiane, Herfarth, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717383/ https://www.ncbi.nlm.nih.gov/pubmed/31470902 http://dx.doi.org/10.1186/s13063-019-3614-y |
Ejemplares similares
-
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2011) -
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study
por: Herfarth, Klaus, et al.
Publicado: (2018) -
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2013) -
Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study
por: Liermann, Jakob, et al.
Publicado: (2020) -
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)